However, a poor response to salvage therapy in patients with relapsed or refractory FLT3-ITD acute myeloid leukemia often prevents them from being bridged to hemopoietic stem-cell transplantation, and according to a previous publication, the best timing of allogeneic hematopoietic cell transplantation is after salvage chemotherapy if CR is achieved [6, 7]. This evidence concerns the gene FLT3 and acute myeloid leukemia.